Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Income (2021 - 2025)

Kiniksa Pharmaceuticals International's Net Income history spans 5 years, with the latest figure at -$71.9 million for Q4 2025.

  • For Q4 2025, Net Income fell 359.34% year-over-year to -$71.9 million; the TTM value through Dec 2025 reached -$27.1 million, down 311.48%, while the annual FY2025 figure was -$27.1 million, 311.48% down from the prior year.
  • Net Income reached -$71.9 million in Q4 2025 per KNSA's latest filing, down from $18.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $224.1 million in Q3 2022 to a low of -$97.0 million in Q4 2022.
  • Average Net Income over 5 years is $8.0 million, with a median of -$12.5 million recorded in 2023.
  • Peak YoY movement for Net Income: skyrocketed 833.67% in 2022, then plummeted 359.34% in 2025.
  • A 5-year view of Net Income shows it stood at $128.0 million in 2021, then plummeted by 175.78% to -$97.0 million in 2022, then surged by 220.01% to $116.4 million in 2023, then plummeted by 76.18% to $27.7 million in 2024, then plummeted by 359.34% to -$71.9 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Net Income are -$71.9 million (Q4 2025), $18.4 million (Q3 2025), and $17.8 million (Q2 2025).